Semaglutide offers a compelling alternative by delivering powerful results without the need for surgery
The landmark cardiovascular outcome trial, SUSTAIN-6, reported that semaglutide led to a marked reduction in major adverse cardiovascular events, such as non-fatal stroke and non-fatal myocardial infarction, among individuals with type 2 diabetes at high cardiovascular risk
In other words, you would receive one month (4 injections) of 0.25 mg, one month (4 injections) of 0.5 mg, and so forth to 1.0 mg, 1.7 mg, and finally 2.4 mg, assuming your side effects are minimal
Thus, truncation of the C-terminal L585 residue of the GLP-1 fusion containing WT albumin reduces its cellular recycling in vitro and plasma half-life in vivo, which may be compensated for by QMP engineering of albumin, irrespective of the presence of L585
If your plan requires it, you'll need to get something called prior authorization